A Phase I / II trial of MYO-029 in adult patients with muscular dystrophy.

###articles. A Phase I / II trial of MYO-029 in adult patients with muscular dystrophy, Kathryn R. James L. Fleckenstein, Anthony A. Richard J. Katharine Bushby, Diana M. Escolar, Kevin M. Flanigan, Alan Pestronk, Rabi Tawil, Michelle Eagle, Julaine M. Florence, Wendy M. Shree Pandya, Volker Straub, Paul Juneau, Kathleen Meyers, Cristina Csimma, Tracey Araujo, Robert Allen, Stephanie A. Parsons, Edward R. La Vallie, Jerry R. Mendell, Annals of Neurology.

courtesy of you, the entire Kaiser Daily Health Policy Report indicate search , or, or sign up for email delivery at Kaiser Daily Health Policy Report strongly supports imperial network. A free service of the Henry J. Released. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.An inorganic polymer, mechanism that blood clots shape.

Polyphosphates platelet plays a key role at inflammation and of formation of blood clots, scientists from the Swedish medical university Karolinska Institutet. The study, which is presented in the renowned scientific journal Cell describes the to how this mechanism be used to treat.

Researchers show that specific enzymes, phosphatases, decomposing polyphosphates may to avoid of both ignition and which blood clot formation in blood vessels in mice. Thus, the researchers believe that phosphatases can be are the focal a new type of treatment of blood clots and inflammation.

Random entries

Other entries from category "physiotherapy":